NASDAQ:REGN

Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases

Retrieved on: 
Tuesday, March 28, 2023
Health, Health Technology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Tissue, Protalix BioTherapeutics, Partnership, Inflammation, Multimedia, Antibody, Ulcerative colitis, Crohn's disease, TCR, Immune system, Entrepreneurship, Autoimmunity, Vaccine, Pharmaceutical industry, Regeneron Pharmaceuticals, Regulatory T cell

Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel regulatory T cell (Treg) therapies for autoimmune diseases.

Key Points: 
  • Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel regulatory T cell (Treg) therapies for autoimmune diseases.
  • The collaboration will bring together Regeneron’s industry-leading VelociSuite®technologies for the discovery and characterization of fully human antibodies and T cell receptors (TCRs) with Sonoma Biotherapeutics’ pioneering approach to developing and manufacturing gene-modified Treg cell therapies.
  • View the full release here: https://www.businesswire.com/news/home/20230328005378/en/
    Under the terms of the agreement, Sonoma Biotherapeutics will receive $75 million in upfront payments, which includes a $30 million equity investment in Sonoma by Regeneron.
  • Regeneron and Sonoma will jointly research and develop Treg cell therapies for ulcerative colitis, Crohn’s disease and two other undisclosed indications, with a Regeneron option for a fifth indication.

Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease

Retrieved on: 
Wednesday, March 15, 2023
Research, Nobel Prize in Chemistry, Machine learning, Society, Regeneron Science Talent Search, Trustee, Climate change, Risk, Injury, Physics, Software, School, Cell, Creativity, Traumatic brain injury, Brain damage, Semantics, Patient, Calculus, Sidhu, Algorithm, Human, National Medal, Student, Nobel Prize, Diagnosis, Society for Science, Science News, Weather, Language, Thought, Suicide, Kawasaki disease, RNA, Intelligence, Culture, Stroke, Caterpillar, Traffic barrier, ARD International Music Competition, Pharmaceutical industry, Birth control, Management, STEM, Chemistry, Regeneron Pharmaceuticals, T3, Science

TARRYTOWN, N.Y. and WASHINGTON, March 14, 2023 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Neel Moudgal, 17, of Saline, Mich., won the top $250,000 award in the 2023 Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors.

Key Points: 
  • The competition, now in its 82nd year, celebrates and rewards young scientists focused on a wide range of scientific topics.
  • "Congratulations to the winners of the Regeneron Science Talent Search 2023," said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News.
  • The Regeneron Science Talent Search empowers young people who are passionate about innovation and using scientific discovery to contribute to improving our world.
  • In total, Regeneron awarded $3.1 million in prizes this year, including $2,000 to each of the top scholars and their schools.

Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition

Retrieved on: 
Tuesday, January 24, 2023
Social, Engineering, Chemistry, Environmental science, Student, Medicine, Prohibition, Molecular biology, Health, Computational biology, Knowledge, Physics, Nobel Prize, COVID-19, Biochemistry, Mathematics, Regeneron Science Talent Search, Neuroscience, Climate change, Genomics, AIDS, Society for Science, Air pollution, School, Creativity, Science News, Society, Research, Pharmaceutical industry, Management, STEM, Science, Regeneron Pharmaceuticals

TARRYTOWN, N.Y. and WASHINGTON, Jan. 24, 2023 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year's Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors. The competition, now in its 82nd year, celebrates and rewards young scientists focused on a wide range of scientific topics from the space race to the AIDS epidemic to climate change. Many past winners continue to pursue innovation for the good of society and the planet, with program alumni receiving some of the world's most coveted science and math honors, including 13 Nobel Prizes and 22 MacArthur Foundation Fellowships, as well as becoming the founders of many important science-based companies, such as Regeneron.

Key Points: 
  • TARRYTOWN, N.Y. and WASHINGTON, Jan. 24, 2023 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year's Regeneron Science Talent Search , the nation's oldest and most prestigious science and math competition for high school seniors.
  • "Congratulations to an exceptional group of Regeneron Science Talent Search 2023 finalists," said George D. Yancopoulos, M.D., Ph.D., Co-founder, President and Chief Scientific Officer of Regeneron, and a 1976 Science Talent Search finalist and top winner.
  • "We are thrilled to welcome this inspiring and highly talented class of Regeneron Science Talent Search finalists," said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News.
  • In total, more than $3 million in awards will be distributed throughout the Regeneron Science Talent Search.

Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma

Retrieved on: 
Monday, December 12, 2022
BCMA, ORR, B-cell maturation antigen, Society, Regeneron Pharmaceuticals, Patient, Multiple myeloma, Ohio State University, Assistant, Division, Bone marrow, B cell, ASH, Risk, Vaccine, Pharmaceutical industry, Hematology

TARRYTOWN, N.Y., Dec. 12, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive initial data from a pivotal Phase 2 expansion cohort evaluating investigational linvoseltamab (formerly REGN5458) at the 200 mg dose recommended for further development in patients with heavily pre-treated, relapsed/refractory (R/R) multiple myeloma. The results were part of a broader presentation of new and updated data from a Phase 1/2 trial and were shared at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA. Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.

Key Points: 
  • Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.
  • "At the recommended 200 mg dose in a pivotal Phase 2 trial, linvoseltamab demonstrated early, deep and durable responses in patients living with multiple myeloma who had been on at least three prior therapies, including those with higher risk and high disease burden.
  • These clinically meaningful outcomes at 12 weeks reinforce the positive linvoseltamab results seen in the Phase 1 dose escalation portion, and we look forward to seeing data from more patients and longer follow-up."
  • The ongoing, open-label, multicenter Phase 1/2 dose-escalation and dose-expansion trial is investigating linvoseltamab in patients with R/R multiple myeloma.

Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year

Retrieved on: 
Monday, December 12, 2022
Civic, Laboratory, Biotechnology, Culture, Allergy, Regeneron Science Talent Search, Infection, Patient, ESG, Science, Cancer, DJSI, Degenerative disease, FDA, Medicine, FTSE4Good Index, Inflammation, Education, Dow Jones, ISEF, Eye, Pharmaceutical industry, Regeneron Pharmaceuticals

TARRYTOWN, N.Y., Dec. 12, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the company has been included on the Dow Jones Sustainability World Index (DJSI World) for the fourth consecutive year and on the Dow Jones Sustainability North America Index (DJSI North America) for the third year. These indices recognize Regeneron's enduring leadership in supporting its patients, colleagues, communities and planet. 

Key Points: 
  • DJSI World recognizes the top 10 percent of most sustainable companies by industry; Regeneron ranked among top three biotechnology companies1
    TARRYTOWN, N.Y., Dec. 12, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.(NASDAQ: REGN) today announced that the company has been included on the Dow Jones Sustainability World Index (DJSI World) for the fourth consecutive year and on the Dow Jones Sustainability North America Index (DJSI North America) for the third year.These indices recognize Regeneron's enduring leadership in supporting its patients, colleagues, communities and planet.
  • Regeneron ranked among the top three biotechnology companies globally.1 Out of the 2,500 largest companies eligible for inclusion on this year's DJSI World Index, Regeneron is one of only six companies in the biotechnology sector selected.
  • "We are proud that Regeneron's long-standing commitment to corporate responsibility has once again been highlighted through inclusion in the Dow Jones Sustainability World Index," saidLeonardS.
  • Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most "community-minded" companies in the U.S.

Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH

Retrieved on: 
Sunday, December 11, 2022

TARRYTOWN, N.Y., Dec. 11, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new and updated data from a Phase 1 and pivotal Phase 2 trial (ELM-1 and ELM-2) evaluating investigational odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). These included first data from a Phase 2 cohort of patients naïve to prior CAR-T therapy (CAR-T naïve), as well as updated data from a dose expansion cohort of a Phase 1 trial in patients who had progressed on CAR-T therapy (post-CAR-T). The results were presented in an oral session at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA, and will form the basis of planned submissions to regulatory authorities in 2023, including to the U.S. Food and Drug Administration (FDA). Odronextamab is an investigational bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.

Key Points: 
  • "The Phase 1 and pivotal Phase 2 odronextamab data demonstrated deep and durable responses that were consistent in patients who progress after CAR-T therapy, which is important as they have particularly difficult-to-treat disease and no effective treatment options.
  • Coupled with its overall safety profile, these clinically important results reinforce the potential of odronextamab to treat this aggressive blood cancer."
  • Results as assessed by independent central review were as follows:
    Among post-CAR-T patients, a 48% ORR, with 32% achieving a CR.
  • Among 140 patients in the Phase 2 cohort assessed for safety, adverse events (AE) occurred in 99% of patients, with 79% being Grade 3.

CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

Retrieved on: 
Thursday, November 17, 2022

SOUTH SAN FRANCISCO, Calif. and TARRYTOWN, N.Y., Nov. 17, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer therapies utilizing CytomX’s Probody® therapeutic platform and Regeneron’s Veloci-Bi® bispecific antibody development platform.

Key Points: 
  • The collaboration is strategically focused on applying CytomXs biologic masking strategies to develop investigational Regeneron bispecifics that remain inactive until activated by proteases in the tumor microenvironment.
  • This collaboration will enable Regeneron and CytomX to combine our collective oncology expertise with two premier platforms Probody and Veloci-Bi to develop novel immunotherapies and research their potential to transform patient lives.
  • Under the agreement, Regeneron and CytomX will collaborate on the discovery activities to identify and validate conditionally active bispecific antibodies.
  • CytomX has also established strategic collaborations with multiple leaders in oncology, including AbbVie, Amgen, Astellas, Bristol Myers Squibb and Regeneron.

Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis

Retrieved on: 
Friday, September 16, 2022

The interim data include 12 adult patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I III heart failure.

Key Points: 
  • The interim data include 12 adult patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I III heart failure.
  • Together with the previously reported data from the polyneuropathy arm of this landmark study, these results strongly suggest that NTLA-2001 could serve as a single-dose treatment regardless of disease manifestation.
  • Intellia and Regeneron are working together diligently to advance this potentially groundbreaking application of CRISPR technology, which could one day be used for many different genetic diseases.
  • The global Phase 1 trial is an open-label, multi-center, two-part study of NTLA-2001 in adults with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) or transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment

Retrieved on: 
Thursday, June 2, 2022
Regeneron Pharmaceuticals, Melanoma, TLR9, GLOBE, Technology, Acquisition, NASDAQ, Kuros, CpG, Pharmaceutical industry, Checkmate

SCHLIEREN (ZURICH), Switzerland, June 02, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, notes the completion of the acquisition of Checkmate Pharmaceuticals (NASDAQ: CMPI) by Regeneron Pharmaceuticals (NASDAQ: REGN). The completion triggers a $5 million milestone payment under a license agreement entered into by Kuros and Checkmate in 2015.

Key Points: 
  • SCHLIEREN (ZURICH), Switzerland, June 02, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (Kuros or the Company), a leader in next generation bone graft technologies, notes the completion of the acquisition of Checkmate Pharmaceuticals (NASDAQ: CMPI) by Regeneron Pharmaceuticals (NASDAQ: REGN).
  • The completion triggers a $5 million milestone payment under a license agreement entered into by Kuros and Checkmate in 2015.
  • Under a royalty purchase agreement entered into by Kuros and XOMA Corporation (NASDAQ: XOMA) in 2021, XOMA is entitled to receive 50% of the milestone payment paid to Kuros as a result of a change of control of Checkmate Pharmaceuticals.
  • Therefore, $2.5 million of the $5 million milestone due to Kuros under the 2015 license agreement will be paid to XOMA.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: American Campus Communities, Inc. (NYSE - ACC), Checkmate Pharmaceuticals, Inc. (Nasdaq - CMPI), Natus Medical Incorporated (Nasdaq - NTUS), Flexible Solutions Intern

Retrieved on: 
Tuesday, April 19, 2022
History of Istanbul, FSI, Blackstone, REGN, GLOBE, Brodsky, Regeneron Pharmaceuticals, Company, Nasdaq, ArchiMate, ACC, Security (finance), Checkmate, Soranik Natu

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • ACC stockholders will receive $65.47 in cash per share, in a transaction valued at approximately $12.8 billion, including the assumption of debt.
  • Under the terms of the agreement, Checkmate will be acquired by Regeneron Pharmaceuticals, Inc. (Nasdaq - REGN).
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.